ONETTO NICOLE 4

Accession 0001193125-25-321154

CIK 0001641281other

View on SEC.gov Company Profile

Filed

Dec 15, 7:00 PM ET

Accepted

Dec 16, 5:14 PM ET

Size

32.8 KB

Accession

0001193125-25-321154

Insider Transaction Report

Form 4

Period: 2025-12-12

Bolt Biotherapeutics, Inc.BOLT

ONETTO NICOLE

Director

Transactions

Award
Director Stock Option (Right to Buy)
2025-12-12+1,393→ 1,393 total
Exercise: $5.44Exp: 2031-12-13→ Common Stock (1,393 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,393→ 0 total
Exercise: $83.80Exp: 2031-12-13→ Common Stock (1,393 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+1,107→ 1,107 total
Exercise: $5.44Exp: 2032-03-23→ Common Stock (1,107 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,107→ 0 total
Exercise: $60.60Exp: 2032-03-23→ Common Stock (1,107 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+611→ 611 total
Exercise: $5.44Exp: 2032-03-23→ Common Stock (611 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−611→ 0 total
Exercise: $60.60Exp: 2032-03-23→ Common Stock (611 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+1,250→ 1,250 total
Exercise: $5.44Exp: 2032-06-09→ Common Stock (1,250 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,250→ 0 total
Exercise: $39.80Exp: 2032-06-09→ Common Stock (1,250 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+1,100→ 1,100 total
Exercise: $5.44Exp: 2034-06-11→ Common Stock (1,100 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,100→ 0 total
Exercise: $15.36Exp: 2034-06-11→ Common Stock (1,100 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+1,100→ 1,100 total
Exercise: $5.44Exp: 2035-05-26→ Common Stock (1,100 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,100→ 0 total
Exercise: $6.40Exp: 2035-05-26→ Common Stock (1,100 underlying)

Footnotes (8)

[F1]The option is fully vested and exercisable.
[F2]The reporting person agreed to cancellation of an option granted on December 14, 2021, in exchange for a new option having a lower exercise price.
[F3]The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price.
[F4]The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price.
[F5]The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price.
[F6]The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price.
[F7]The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
[F8]The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Bolt Biotherapeutics, Inc.

CIK 0001641281

→

Entity typeother

Related Parties

filerCIK 0001220049

Filing Metadata

Form type: 4
Filed: Dec 15, 7:00 PM ET
Accepted: Dec 16, 5:14 PM ET
Size: 32.8 KB

View on SEC.gov